10. Struewing, J.P., Abeliovich, D., Peretz, Т., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200;

http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

11. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

12. www.mercola.com/2002/apr/27/sv40.htm

13. Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.

14. Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

15. Cheesernan, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

16. Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh, 95B, 231–237.

17. Miller, W R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.

18. Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.

19. Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer.Journal of Steroid Biochemistry, 23, 1169–1172.

20. Miller, WR. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, WR. and Berchuck, A. (editors). New York: CRC Press.

21. Miller, WR., 1991. Oestrogens and breast cancer: biological considerations, British Medical Bulletin, 47, 470–483.

22. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

23. Rose, Steven, with Mileusnic, Radmila, 1999. The Chemistry of Life. Fourth (revised) edition. Penguin Books.

24. Voet, Donald and Voet, Judith, 1995. Biochemistry. Second edition. John Wiley & Sons, Inc.

25. Jiang, Wen G., Matsumoto, Kunio and Nakamura, Toshikazu (editors), 2001, Growth Factors and their Receptors in Cancer Metastasis. Dordrecht: Kluwer Academic Publishers.

26. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

27. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

28. www.ucop.edu/srphome/bcrp/progressreport/abstracts/ innov/3CB-0186.html

29. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

30. www.preventcancer.com/pdf/InsulinGrowth266.html

1. www.dep.iarc.fr/globocan/database.pdf

2. WHO International Agency for Research on Cancer (IARC), IARC Cancer Epidemiology Database. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Ferlay, J., Bray, F., Piesci, P. and Parkin, D.M. (editors), www.dep.iarc. fr/globocan/ database.pdf

3. American Cancer Society. Modelled data: cancer facts and figures, 2006.

4. www.cancerresearchuk.org

5. www.cancerresearchuk.org

6. www.cancerresearchuk.org

7. Pike M.C., Kolonel, L.N., Henderson, B.E., Wilkens, L.R., Hankin J.H., Feigelson, H.S., Wan, P.C., Stram, D.O. and Nomura, A.M., 2002. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev, 11 (9), 795–800.

8. www.hawaii.edu/crch/ProfileKolonel.htm